Wegovy Weight Loss Calculator

The three trials enrolled similar populations but not identical ones. STEP 1 averaged about 232 lb at baseline, OASIS-4 about 235 lb, and STEP UP a noticeably heavier 248 lb. They also ran for different lengths, which is why the columns below stop where they do.

One number worth knowing before you read the 7.2 mg column as a straight upgrade: STEP UP included its own 2.4 mg arm, which lost 15.5%, not STEP 1's 14.9%. Compared inside that single trial, the step from 2.4 mg to 7.2 mg is worth about 3.3 percentage points, which is a good deal smaller than the gap you get by reading the two trials against each other.

Nobody starts at the maintenance dose. The 2.4 mg injection climbs for 16 weeks (0.25, 0.5, 1, 1.7, then 2.4 from week 17). Wegovy HD climbs for 20 weeks. The tablet is quickest at 12 weeks. The schedules exist to limit nausea, but they do mean a good chunk of your first year is spent below the dose the trial is named after.

So the early weeks are not a preview of the later ones. At week 12 the estimated 2.4 mg trajectory is about 7.7%, roughly half the eventual average, and at that point you are still on 1 mg. The tablet runs slightly ahead early, at about 8.4% by week 12, precisely because it reaches its full dose sooner, and then finishes lower.

Set the week slider to where you actually are, then watch your own trend against the curve at the same week rather than against the headline.

On the 2.4 mg injection at 68 weeks, 83.5% of participants lost at least 5%, 66.1% of participants lost at least 10%, 47.9% of participants lost at least 15%, and 30.2% of participants lost at least 20%. Around one in six did not reach 5%. Same dose, same trial.

The higher dose shifts the whole distribution rather than just the average: on Wegovy HD, 45.5% lost at least 20% against 30.2% on 2.4 mg in STEP 1. The tablet sits closest to the 2.4 mg injection, with 59.8% losing at least 10%.

All of these are the conservative intention-to-treat numbers from the FDA label, which count everyone randomised including people who stopped taking the medication. Figures quoted around 17% for STEP 1, 20.7% for STEP UP, or 16.6% for the tablet come from adherence-based estimands that only count people who stayed on treatment. We use the lower set throughout.

Tracking your own curve is what makes any of this useful. GlucoPal is a free iPhone app that logs weight, doses, meals, and side effects in one place with a doctor-ready export, and it covers the injections and the tablet.

This is the one comparison that does not depend on reading two separate trials against each other. SURMOUNT-5 put tirzepatide and semaglutide head to head in the same study: 751 adults with obesity and without diabetes, 72 weeks, both titrated to their maximum tolerated dose. Tirzepatide averaged 20.2% against semaglutide's 13.7%, and 19.7% of the tirzepatide group lost at least 30% of their body weight against 6.9% on semaglutide.

An important caveat: SURMOUNT-5 ran before Wegovy HD existed, so its semaglutide arm was capped at 2.4 mg. It is a head-to-head of tirzepatide against the older semaglutide dose, not against the 7.2 mg one. No published trial has yet compared tirzepatide with Wegovy HD.

None of which settles the choice for an individual. Tolerability, cost, insurance coverage, availability, and whether you would rather take a weekly injection or a daily tablet all matter, and plenty of people do very well on semaglutide. That is a conversation for your prescriber.

Ozempic and Rybelsus. Both are semaglutide, but at lower doses and without an approved weight-loss indication, so there is no pivotal weight-loss trial at those doses to draw a curve from. If you are on either, the Wegovy 2.4 mg curve is the closest published reference, and it will overstate what those doses were studied to do.

Compounded semaglutide. No pivotal trials of its own, so there is no published curve to model. The trial data here describes the branded products that were actually studied.

If you are on the tablet, our Wegovy pill tracker guide covers the day-to-day differences, and side-effect tracking matters most during the escalation weeks whichever form you take.

It is a reference point, not a forecast. Every trial endpoint and every responder percentage above is a published number taken from the FDA label. Everything in between is estimated: none of these trials publish a week-by-week numeric table, only figures. We fit a saturating weight-loss curve through the verified anchors, hit each published endpoint exactly, and label every intermediate week as estimated.

The 7.2 mg and tablet curves are newer and correspondingly less well anchored than the 2.4 mg one, which has a verified week-20 value from the European regulator's assessment to hold its shape in place. For those two we set the curve shape from each trial's escalation schedule and normalise to the published endpoint.

The trial populations may also not match yours, and the numbers reflect medication plus a structured diet and activity programme rather than medication alone. This is educational information, not medical advice.